Unpacking the Legal Fallout of a Disgraced Drugmaker

This chapter explores the groundbreaking investigation into INSYS, focusing on how federal authorities relied on a whistleblower to build their case against the drugmaker's executives. It also examines the broader consequences of the opioid epidemic and raises critical questions about pharmaceutical influence in medical education.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.